Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1969 Jan 11;1(5636):88–91. doi: 10.1136/bmj.1.5636.88

Plasminogen-activator-producing Tumour

J F Davidson, G P McNicol, G L Frank, T J Anderson, A S Douglas
PMCID: PMC1982019  PMID: 5761832

Abstract

In a patient with giant-cell carcinoma of the lung a secondary tumour deposit in the arm was incised and bled for three weeks. Investigations showed the tumour to be rich in plasminogen activator. Haemostasis in the tumour was achieved with aminocaproic acid therapy. For a period the plasminogen-activator properties were retained in cell culture of the tumour.

Full text

PDF
90

Images in this article

90Fig. 3
on p.90

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernik M. B., Kwaan H. C. Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med. 1967 Oct;70(4):650–661. [PubMed] [Google Scholar]
  2. FRIEDBERG E. C. GIANT-CELL CARCINOMA OF THE LUNG: A DEDIFFERENTIATED ADENOCARCINOMA. Cancer. 1965 Feb;18:259–264. doi: 10.1002/1097-0142(196502)18:2<259::aid-cncr2820180219>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  3. GREENBERG E., DIVERTIE M. B., WOOLNER L. B. A REVIEW OF UNUSUAL SYSTEMIC MANIFESTATIONS ASSOCIATED WITH CARCINOMA. Am J Med. 1964 Jan;36:106–120. doi: 10.1016/0002-9343(64)90153-6. [DOI] [PubMed] [Google Scholar]
  4. HELLSTROM H. R., FISHER E. R. GIANT CELL CARCINOMA OF LUNG. Cancer. 1963 Aug;16:1080–1088. doi: 10.1002/1097-0142(196308)16:8<1080::aid-cncr2820160816>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  5. MCNICOL G. P., BARAKAT A. A., DOUGLAS A. S. PLASMA FIBRINOLYTIC ACTIVITY IN RENAL DISEASE. Scott Med J. 1965 May;10:189–194. doi: 10.1177/003693306501000502. [DOI] [PubMed] [Google Scholar]
  6. MOSCONA A. Rotation-mediated histogenetic aggregation of dissociated cells. A quantifiable approach to cell interactions in vitro. Exp Cell Res. 1961 Jan;22:455–475. doi: 10.1016/0014-4827(61)90122-7. [DOI] [PubMed] [Google Scholar]
  7. MULLERTZ S. Activation of plasminogen. Ann N Y Acad Sci. 1957 Aug 30;68(1):38–51. doi: 10.1111/j.1749-6632.1957.tb42611.x. [DOI] [PubMed] [Google Scholar]
  8. Merskey C., Kleiner G. J., Johnson A. J. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood. 1966 Jul;28(1):1–18. [PubMed] [Google Scholar]
  9. NASH A. D., STOUT A. P. Giant cell carcinoma of the lung; report of 5 cases. Cancer. 1958 Mar-Apr;11(2):369–376. doi: 10.1002/1097-0142(195803/04)11:2<369::aid-cncr2820110222>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  10. O'MEARA R. A., THORNES R. D. Some properties of the cancer coagulative factor. Ir J Med Sci. 1961 Mar;423:106–112. doi: 10.1007/BF02952952. [DOI] [PubMed] [Google Scholar]
  11. Puck T. T., Marcus P. I. A RAPID METHOD FOR VIABLE CELL TITRATION AND CLONE PRODUCTION WITH HELA CELLS IN TISSUE CULTURE: THE USE OF X-IRRADIATED CELLS TO SUPPLY CONDITIONING FACTORS. Proc Natl Acad Sci U S A. 1955 Jul 15;41(7):432–437. doi: 10.1073/pnas.41.7.432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. TAGNON H. J., SCHULMAN P., WHITMORE W. F., LEONE L. A. Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. Am J Med. 1953 Dec;15(6):875–884. doi: 10.1016/0002-9343(53)90178-8. [DOI] [PubMed] [Google Scholar]
  13. TODD A. S. LOCALIZATION OF FIBRINOLYTIC ACTIVITY IN TISSUES. Br Med Bull. 1964 Sep;20:210–212. doi: 10.1093/oxfordjournals.bmb.a070333. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES